
    
      This research proposal will investigate a glutamate-modulating agent, riluzole, in
      treatment-resistant patients who exhibit an acute, sustained response to a single dose of
      intravenous (IV) racemic ketamine. Fifty ketamine-responders will be randomized to riluzole
      or placebo in a 4-week, randomized, double-blind, continuation-phase study.
    
  